Evidence map›Paper›PMID 35008621›Full record

ArticleInternational journal of molecular sciences2021

Analyses and Correlation of Pathologic and Ocular Cutaneous Changes in Murine Graft versus Host Disease.

Robert B Levy, Hazem M Mousa, Casey O Lightbourn, Eric J Shiuey, David Latoni, Stephanie Duffort, Ryan Flynn, Jing Du, Henry Barreras, Michael Zaiken and 3 more

Open access · goldAbstract readComparative Study
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. A Novel Murine Model for Lupus-Like Ocular Chronic Graft-Versus-Host Disease.Investigative ophthalmology & visual science · 2024
    Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Robert B LevyDepartment of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL 33101, USA.
Hazem M MousaSchool of Medicine, Duke University, Durham, NC 27708, USA.
Casey O LightbournDepartment of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL 33101, USA.
Eric J ShiueySchool of Medicine, Duke University, Durham, NC 27708, USA.ORCID 0000-0002-4612-1321
David LatoniSchool of Medicine, Duke University, Durham, NC 27708, USA.
Stephanie DuffortDepartment of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL 33101, USA.
Ryan FlynnDepartment of Pediatrics, Division of Blood & Marrow Transplant & Cellular Therapy, University of Minnesota, Minneapolis, MN 55455, USA.
Jing DuDepartment of Pediatrics, Division of Blood & Marrow Transplant & Cellular Therapy, University of Minnesota, Minneapolis, MN 55455, USA.
Henry BarrerasDepartment of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL 33101, USA.
Michael ZaikenDepartment of Pediatrics, Division of Blood & Marrow Transplant & Cellular Therapy, University of Minnesota, Minneapolis, MN 55455, USA.ORCID 0000-0001-6971-3170
Katelyn PazDepartment of Pediatrics, Division of Blood & Marrow Transplant & Cellular Therapy, University of Minnesota, Minneapolis, MN 55455, USA.
Bruce R BlazarDepartment of Pediatrics, Division of Blood & Marrow Transplant & Cellular Therapy, University of Minnesota, Minneapolis, MN 55455, USA.ORCID 0000-0002-9608-9841
Victor L PerezSchool of Medicine, Duke University, Durham, NC 27708, USA.
University of Minnesota · USDuke University · USUniversity of Miami · US

Funding

Transgenic/KnockoutP01AI056299 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI BLAZAR, BRUCE R · 2003 to 2023
$42.5M
Enhancing Treg Therapeutic Efficacy in GVHDR01HL118979 · NHLBI · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, HIPPEN, KELI L · 2014 to 2025
$6.7M
T-CELL TARGETING FOR GVHDR01HL056067 · NHLBI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI BLAZAR, BRUCE R · 1995 to 2022
$5.4M
Immune Mechanisms in Ocular Graft versus Host DiseaseR01EY024484 · NEI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI LEVY, ROBERT BENJAMIN, PEREZ, VICTOR L · 2014 to 2025
$5.1M
Local regulation and deletion of T cells to induce tolerance and establish long-term survival of high-risk corneal transplantsR01EY030283 · NEI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Robert Benjamin Levy, Victor L Perez · 2020 to 2026
$3.1M
NEI NIH HHS R01 EY024484NEI NIH HHS R01 EY030283NHLBI NIH HHS R01 HL056067NHLBI NIH HHS R01 HL118979NIAID NIH HHS P01 AI056299NIH HHS R01-EY030283-01NIH HHS R41AI149916-01NIH HHS RO1-EY024484-06
6 · The paper itself

Abstract

Graft versus host disease (GVHD) is initiated by donor allo-reactive T cells activated against recipient antigens. Chronic GVHD (cGVHD) is characterized by immune responses that may resemble autoimmune features present in the scleroderma and Sjogren's syndrome. Unfortunately, ocular involvement occurs in approximately 60-90% of patients with cGVHD following allo-hematopoietic stem cell transplants (aHSCT). Ocular GVHD (oGVHD) may affect vision due to ocular adnexa damage leading to dry eye and keratopathy. Several other compartments including the skin are major targets of GVHD effector pathways. Using mouse aHSCT models, the objective was to characterize cGVHD associated alterations in the eye and skin to assess for correlations between these two organs. The examination of multiple models of MHC-matched and MHC-mismatched aHSCT identified a correlation between ocular and cutaneous involvement accompanying cGVHD. Studies detected a "positive" correlation, i.e., when cGVHD-induced ocular alterations were observed, cutaneous compartment alterations were also observed. When no or minimal ocular signs were detected, no or minimal skin changes were observed. In total, these findings suggest underlying cGVHD-inducing pathological immune mechanisms may be shared between the eye and skin. Based on the present observations, we posit that when skin involvement is present in aHSCT patients with cGVHD, the evaluation of the ocular surface by an ophthalmologist could potentially be of value.

Indexed as

InflammationAnimalsDisease Models, AnimalDry Eye SyndromesEyeGraft vs Host DiseaseMiceSkinTransplantation, Homologouscorrelationcutaneous GVHDinflammationocular GVHDocular immune responsepathology

Identifiers

PMID35008621
PMCPMC8745722
OpenAlexW4200005390

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.